ArticleCell reports2021
Dysregulated oxalate metabolism is a driver and therapeutic target in atherosclerosis.
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 46 citations in OpenAlex.
- Metabolic Pathways Linking Atherosclerotic Cardiovascular Disease With Metabolic Dysfunction-Associated Steatotic Liver Disease.Current atherosclerosis reports · 2026Review
- Oxalate as an Emerging Contributor to Cardiovascular Disease: Links to Inflammation, Immunity, and Oxidative Stress.Nutrients · 2026Review
- Sex-based multiomics analysis uncovers metabolic and molecular mediators linking MASH and atherosclerosis.JHEP reports : innovation in hepatology · 2026Article
- Targeting Oxalate Production by Combining Enzyme Inhibition and Proteolysis Activation: A Novel Therapeutic Approach for Primary Hyperoxaluria Type 1.Journal of medicinal chemistry · 2026Article
- Predicting probiotic success: lessons from Oxalobacter and oxalate metabolism.NPJ biofilms and microbiomes · 2026Review
- Article
- R-spondin 2 suppresses hepatic steatosis via activation of AMPK-ACC signaling.JHEP reports : innovation in hepatology · 2025Article
- Article
- Recent Advances and Perspectives of Metabolomics-Based Investigations in Coronary Heart Disease.Current atherosclerosis reports · 2025Review
- Colonization withbioRxiv : the preprint server for biology · 2025Article
- Complex system modeling reveals oxalate homeostasis is driven by diverse oxalate-degrading bacteria.eLife · 2025Article
- Article
- Nidogen 2 Overexpression Promotes Hepatosteatosis and Atherosclerosis.International journal of molecular sciences · 2024Article
- Inhibition of hepatic oxalate overproduction ameliorates metabolic dysfunction-associated steatohepatitis.Nature metabolism · 2024Article
- Bacterial Degradation of Antinutrients in Foods: The Genomic Insight.Foods (Basel, Switzerland) · 2024Review
- Interleukin-16 is increased in dialysis patients but is not a cardiovascular risk factor.Scientific reports · 2024Article
- Amino Acid Metabolism and Atherosclerotic Cardiovascular Disease.The American journal of pathology · 2024Review
- Dysregulated cellular metabolism in atherosclerosis: mediators and therapeutic opportunities.Nature metabolism · 2024Review
- Article
- Gut Microbiota's Oxalate-Degrading Activity and Its Implications on Cardiovascular Health in Patients with Kidney Failure: A Pilot Prospective Study.Medicina (Kaunas, Lithuania) · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 8 institutions in 3 countries.
Yuhao LiuDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Cardiovascular Medicine, The Second Xiangya Hospital, Central South University, Changsha 410000, China.
Ying ZhaoDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Yousef ShukhaDepartment of Internal Medicine E, Rambam Health Care Campus, Haifa 3109601, Israel; The Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel.
Haocheng LuDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Lu WangCollege of Pharmacy, Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
Zhipeng LiuDepartment of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN 47907, USA.
Cai LiuCollege of Pharmacy, Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
Yang ZhaoDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Huilun WangDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Guizhen ZhaoDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Wenying LiangDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Yanbo FanDepartment of Cancer Biology, College of Medicine, University of Cincinnati, Cincinnati, OH 45267, USA.
Lin ChangDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Arif YurdagulDepartment of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA 71103, USA.
Christopher B PattilloDepartment of Molecular and Cellular Physiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA 71103, USA.
A Wayne OrrDepartment of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA 71103, USA.
Michael AviramThe Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel.
Bo WenCollege of Pharmacy, Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
Minerva T Garcia-BarrioDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Jifeng ZhangDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA.
Wanqing LiuDepartment of Pharmaceutical Sciences and Department of Pharmacology, Wayne State University, Detroit, MI 48201, USA.
Duxin SunCollege of Pharmacy, Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA.
Tony HayekDepartment of Internal Medicine E, Rambam Health Care Campus, Haifa 3109601, Israel; The Lipid Research Laboratory, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3525433, Israel.
Y Eugene ChenDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: echenum@umich.edu.
Oren RomDepartment of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology and Translational Pathobiology, Louisiana State University Health Sciences Center-Shreveport, Shreveport, LA 71103, USA. Electronic address: oren.rom@lsuhs.edu.
University of Michigan–Ann Arbor · USLouisiana State University Health Sciences Center Shreveport · USRappaport Family Institute for Research in the Medical Sciences · ILPurdue University West Lafayette · USRambam Health Care Campus · ILSecond Xiangya Hospital of Central South University · CNUniversity of Cincinnati · USWayne State University · US
Funding
Using genetics to discover mechanisms of myocardial infarctionR01HL109946 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI YUQING Eugene CHEN, Ida Liisa Surakka · 2011 to 2026
$8.9MMichigan Mouse Metabolic Phenotyping CenterU2CDK110768 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ELIAS, CAROL FUZETI · 2016 to 2021
$6.2MKLF14 and Cardiovascular DiseaseR01HL134569 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHEN, YUQING EUGENE · 2017 to 2024
$5.3MNck Adaptor Proteins in Atherogenic Endothelial ActivationR01HL133497 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2016 to 2024
$3.8MMatrix Signaling in Endothelial Cell DysfunctionR01HL098435 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2010 to 2020
$3.2MIDOL and dyslipidemia in cardiovascular diseasesR01HL147527 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHEN, YUQING EUGENE · 2019 to 2022
$3.1MKruppel-like factor 11 (KLF11) and atherosclerosisR01HL138139 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ZHANG, JIFENG · 2017 to 2021
$2.3MThe Role of TM6SF2 in Cardiovascular DiseaseR01HL137214 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHEN, YUQING EUGENE · 2017 to 2020
$2.2MThe role of TFEB in aortic aneurysmsR01HL145176 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, YANBO · 2019 to 2022
$2.2MTranscription Factor-EB and Postischemic AngiogenesisR01HL138094 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FAN, YANBO · 2017 to 2021
$2.2MFatty Acid Desaturase 1 (FADS1) Variants and Non-alcoholic Fatty Liver DiseaseR01DK106540 · NIDDK · WAYNE STATE UNIVERSITY · PI LIU, WANQING · 2016 to 2020
$1.9MEphA2 signaling in atherosclerotic fibroproliferative remodelingR01HL141155 · NHLBI · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ORR, ANTHONY WAYNE · 2019 to 2022
$1.8MNHLBI NIH HHS K99 HL150233NHLBI NIH HHS R00 HL145131NHLBI NIH HHS R00 HL150233NHLBI NIH HHS R01 HL098435NHLBI NIH HHS R01 HL109946NHLBI NIH HHS R01 HL133497NHLBI NIH HHS R01 HL134569NHLBI NIH HHS R01 HL137214NHLBI NIH HHS R01 HL138094NHLBI NIH HHS R01 HL138139NHLBI NIH HHS R01 HL141155NHLBI NIH HHS R01 HL145176NHLBI NIH HHS R01 HL147527NIDDK NIH HHS R01 DK106540NIDDK NIH HHS U2C DK110768
Abstract
Dysregulated glycine metabolism is emerging as a common denominator in cardiometabolic diseases, but its contribution to atherosclerosis remains unclear. In this study, we demonstrate impaired glycine-oxalate metabolism through alanine-glyoxylate aminotransferase (AGXT) in atherosclerosis. As found in patients with atherosclerosis, the glycine/oxalate ratio is decreased in atherosclerotic mice concomitant with suppression of AGXT. Agxt deletion in apolipoprotein E-deficient (Apoe
Indexed as
Molecular Targeted TherapyAnimalsAortaApolipoproteins EAtherosclerosisBile Acids and SaltsCell LineChemokine CCL5CholesterolDependovirusFemaleGlycineHomeostasisHumansInflammationMacrophagesAlanine-glyoxylate transaminaseApolipoproteins EBile Acids and SaltsChemokine CCL5CholesterolGlycineOxalatesSuperoxidesTransaminasesAGXTamino acidsatherosclerosisCCL5glycinemitochondrial dysfunctionoxalate
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.